95 related articles for article (PubMed ID: 7498466)
41. The integrin alpha IIb beta 3 contains distinct and interacting binding sites for snake-venom RGD (Arg-Gly-Asp) proteins. Evidence that the receptor-binding characteristics of snake-venom RGD proteins are related to the amino acid environment flanking the sequence RGD.
Rahman S; Lu X; Kakkar VV; Authi KS
Biochem J; 1995 Nov; 312 ( Pt 1)(Pt 1):223-32. PubMed ID: 7492316
[TBL] [Abstract][Full Text] [Related]
42. Solution structure of a cyclic RGD peptide that inhibits platelet aggregation.
Jois SD; Tambunan US; Chakrabarti S; Siahaan TJ
J Biomol Struct Dyn; 1996 Aug; 14(1):1-11. PubMed ID: 8877556
[TBL] [Abstract][Full Text] [Related]
43. [Anticoagulant and fibrinolytic effects of proline-containing peptides].
Pastorova VE; Liapina LA; Smolina TIu; Ashmarin IP
Izv Akad Nauk Ser Biol; 1998; (3):390-4. PubMed ID: 9644912
[TBL] [Abstract][Full Text] [Related]
44. Decompression inducible platelet aggregation (DIPA) is inhibited by Arg-Gly-Asp.
Murayama M
Prog Clin Biol Res; 1988; 283():203-9. PubMed ID: 3211951
[No Abstract] [Full Text] [Related]
45. Synthesis of novel peptide inhibitors of thrombin-induced platelet activation.
Burke FM; Warnock M; Schmaier AH; Mosberg HI
Chem Biol Drug Des; 2006 Nov; 68(5):235-8. PubMed ID: 17177882
[TBL] [Abstract][Full Text] [Related]
46. Mechanism of action of the antiplatelet peptide, arietin, from Bitis arietans venom.
Huang TF; Wang WJ; Teng CM; Ouyang C
Biochim Biophys Acta; 1991 May; 1074(1):144-50. PubMed ID: 2043664
[TBL] [Abstract][Full Text] [Related]
47. Flanking proline residues identify the L-type Ca2+ channel binding site of calciseptine and FS2.
Kini RM; Caldwell RA; Wu QY; Baumgarten CM; Feher JJ; Evans HJ
Biochemistry; 1998 Jun; 37(25):9058-63. PubMed ID: 9636051
[TBL] [Abstract][Full Text] [Related]
48. Chemical synthesis of echistatin, a potent inhibitor of platelet aggregation from Echis carinatus: synthesis and biological activity of selected analogs.
Garsky VM; Lumma PK; Freidinger RM; Pitzenberger SM; Randall WC; Veber DF; Gould RJ; Friedman PA
Proc Natl Acad Sci U S A; 1989 Jun; 86(11):4022-6. PubMed ID: 2726764
[TBL] [Abstract][Full Text] [Related]
49. The relative orientation of the Arg and Asp side chains defined by a pseudodihedral angle as a key criterion for evaluating the structure-activity relationship of RGD peptides.
Kostidis S; Stavrakoudis A; Biris N; Tsoukatos D; Sakarellos C; Tsikaris V
J Pept Sci; 2004 Aug; 10(8):494-509. PubMed ID: 15347137
[TBL] [Abstract][Full Text] [Related]
50. KRDS, a new peptide derived from human lactotransferrin, inhibits platelet aggregation and release reaction.
Mazoyer E; Lévy-Toledano S; Rendu F; Hermant L; Lu H; Fiat AM; Jollès P; Caen J
Eur J Biochem; 1990 Nov; 194(1):43-9. PubMed ID: 2174781
[TBL] [Abstract][Full Text] [Related]
51. Positional importance of Pro53 adjacent to the Arg49-Gly50-Asp51 sequence of rhodostomin in binding to integrin alphaIIbbeta3.
Chang CP; Chang JC; Chang HH; Tsai WJ; Lo SJ
Biochem J; 2001 Jul; 357(Pt 1):57-64. PubMed ID: 11415436
[TBL] [Abstract][Full Text] [Related]
52. Effect of synthetic peptides corresponding to residues 313-332 of the alphaIIb subunit on platelet activation and fibrinogen binding to alphaIIbbeta3.
Mitsios JV; Tambaki AP; Abatzis M; Biris N; Sakarellos-Daitsiotis M; Sakarellos C; Soteriadou K; Goudevenos J; Elisaf M; Tsoukatos D; Tsikaris V; Tselepis AD
Eur J Biochem; 2004 Feb; 271(4):855-62. PubMed ID: 14764102
[TBL] [Abstract][Full Text] [Related]
53. Correlation of molecular shape with GPIIb-IIIa receptor antagonist activity in RGD peptides.
Tung JS; Jakubowski JA; Heath WF; Utterback BG; Herron DK
Receptor; 1993; 3(4):343-56. PubMed ID: 8142908
[TBL] [Abstract][Full Text] [Related]
54. Arg-Gly-Asp-Ser peptide analogs suppress cartilage chondrolytic activities of integrin-binding and nonbinding fibronectin fragments.
Homandberg GA; Hui F
Arch Biochem Biophys; 1994 Apr; 310(1):40-8. PubMed ID: 8161219
[TBL] [Abstract][Full Text] [Related]
55. Chimeric derivative of fibrolase, a fibrinolytic enzyme from southern copperhead venom, possesses inhibitory activity on platelet aggregation.
Swenson S; Bush LR; Markland FS
Arch Biochem Biophys; 2000 Dec; 384(2):227-37. PubMed ID: 11368309
[TBL] [Abstract][Full Text] [Related]
56. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets.
Plow EF; Pierschbacher MD; Ruoslahti E; Marguerie GA; Ginsberg MH
Proc Natl Acad Sci U S A; 1985 Dec; 82(23):8057-61. PubMed ID: 3877935
[TBL] [Abstract][Full Text] [Related]
57. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents.
Lam SC; Dieter JP; Strebel LC; Taylor TM; Muscolino G; Feinberg H; Le Breton GC
J Pharmacol Exp Ther; 1991 Dec; 259(3):1371-8. PubMed ID: 1762085
[TBL] [Abstract][Full Text] [Related]
58. Structural studies of a neuropeptide precursor protein with an RGD proteolytic site.
Zachariah C; Cameron A; Lindberg I; Kao KJ; Beinfeld MC; Edison AS
Biochemistry; 2001 Jul; 40(30):8790-9. PubMed ID: 11467939
[TBL] [Abstract][Full Text] [Related]
59. Pyrazole derivatives as inhibitors of arachidonic acid-induced platelet aggregation.
Levent S; Çalışkan B; Çiftçi M; Özkan Y; Yenicesu I; Ünver H; Banoglu E
Eur J Med Chem; 2013 Jun; 64():42-53. PubMed ID: 23639653
[TBL] [Abstract][Full Text] [Related]
60. Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity.
Wang WY; Hsieh PW; Wu YC; Wu CC
Biochem Pharmacol; 2007 Aug; 74(4):601-11. PubMed ID: 17601492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
